Skip to main content
RXRX
NASDAQ Life Sciences

Recursion Q3: Revenue Beat, $561.5M Cash, Tempus Deal Restructured, Controls Still Weak

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$3.82
Mkt Cap
$2.29B
52W Low
$2.77
52W High
$5.76
52W Position info
38% above low
Off High info
34% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

RXRX sits 38% above its 52-week low of $2.77.

Summary

Recursion's Q3 10-Q confirms the revenue beat and shows $561.5 million of cash after a $264.5 million nine-month burn, with the October offering adding $187.2 million net. The filing also details a restructured Tempus data deal and confirms Exscientia-related material weaknesses remain unremediated.


Key Events · Earnings and Guidance · RXRX

  • Q3 Revenue Jumps on Sanofi Milestone

    Total revenue was $18.552 million versus $5.175 million a year ago, driven by a $10.0 million Sanofi immunology development-candidate milestone; net loss narrowed to $119.036 million from $162.253 million.

  • Cash Falls but Burn Slows

    Cash, equivalents and restricted cash totaled $561.5 million at September 30, 2026, down from $753.9 million at December 31, 2025; nine-month operating cash use was $264.5 million versus $325.7 million a year earlier.

  • October Offering Adds $187.2M Net

    The company completed the sale of 61.5 million Class A shares on October 16, 2026 for net proceeds of approximately $187.2 million; the TD Cowen ATM still has $213.3 million available after $85.5 million of net sales in the first nine months.

  • Tempus Deal Rewritten, Fees Cut

    The September 15, 2026 amendment extends the Tempus data agreement to six years and removes termination for convenience, while cutting annual license fees to $14.0 million for years three through five, with at least $4.0 million payable in cash and the balance payable in stock or cash at Recursion's election.


Analysis · RXRX · Life Sciences

The headline numbers were already out via the same-day 8-K, but the 10-Q is where the balance sheet and the fine print land. Cash and restricted cash fell to $561.5 million from $753.9 million at year-end, and the company burned $264.5 million on operations in nine months — a slower burn than the $325.7 million a year ago, helped by R&D down 18% and G&A down 22%. The October offering added $187.2 million net, which is what actually pushes runway past the twelve-month minimum the filing itself commits to. Two items deserve attention beyond the P&L: Recursion rewrote its Tempus data deal, extending the term to six years and giving up its right to walk away, in exchange for cutting the annual fee to $14.0 million for years three through five (at least $4.0 million in cash, the rest payable in stock at Recursion's election) — a real cash-cost saving but a new source of share issuance. And management again concluded disclosure controls were ineffective because the Exscientia-era material weaknesses are not yet remediated, which keeps a governance overhang in place.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RXRX was trading at $3.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $2.77 to $5.76. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RXRX - Latest Insights

RXRX
Nov 02, 2026, 4:32 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.83
Real-time Price: $2.69 info
Change: -$1.14 (-30%) info
Market Cap: $1.696B info
RXRX
Nov 02, 2026, 4:31 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $3.80
Real-time Price: $2.69 info
Change: -$1.11 (-29%) info
Market Cap: $1.696B info
RXRX
Nov 02, 2026, 4:25 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.83
Real-time Price: $2.69 info
Change: -$1.14 (-30%) info
Market Cap: $1.696B info
RXRX
Oct 16, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.17
Real-time Price: $2.69 info
Change: -$1.48 (-35%) info
Market Cap: $1.696B info
RXRX
Oct 15, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $2.69 info
Change: -$1.03 (-28%) info
Market Cap: $1.696B info